par Shop Apotheke Europe N.V. (isin : NL0012044747)
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Change in Forecast/Strategic Company Decision
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
03-Oct-2024 / 21:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Sevenum, the Netherlands, 3 October 2024. The Management Board of Redcare Pharmacy has decided to intensify marketing investments for its e-Rx business in Germany in Q4 based on very convincing metrics, specifically the repeat order rate and average basket size. This decision is driven by the firm belief that the right investments now will result in further profitable growth and expansion of Redcare Pharmacy’s market leadership.
The Management Board of Redcare Pharmacy has updated the full-year guidance for 2024 as follows:
- Total Group sales of EUR 2.35 to EUR 2.5 billion (previously, EUR 2.3 to EUR 2.5 billion).
- Non-Rx sales growth of 20-25% (previously 15-25%).
- MediService sales to grow by lower half of single digits (previously mid-single digits).
- Adjusted EBITDA margin of 1.2-2.2% (previously 2-4%).
- Rx too dynamic to give guidance (unchanged).
Contact:
rikutis consulting
Thomas Schnorrenberg
Cel: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com
End of Inside Information
Information and Explanation of the Issuer to this announcement:
A live conference call and webcast will be held on 4 October 2024 at 11h00 (CEST), followed by a Q&A session. The presentation is available for download on the Redcare Pharmacy website
(https://ir.redcare-pharmacy.com/en/event-and-publication).
Webcast link to the livestream:
https://www.webcast-eqs.com/redcarepharmacy-2024-q3-tradingupdate
Registration link for participants of the conference call:
03-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2001745 |
| End of Announcement | EQS News Service |
2001745 03-Oct-2024 CET/CEST